Aktuellt
SENASTE
Redeye maintains Orexo's fair value per share at SEK 80 after the Q1 report this morning, because we base our valuation on a long-term view and conservative assumptions. However, in order to maintain investor confidence, Orexo needs to show in the coming months that it can deliver on its strategy to stabilise Zubsolv revenue and that the digital therapies are gaining traction.
LÄS MER
